Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: A single‐institution retrospective study of 21 cases
Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: A single‐institution retrospective study of 21 cases
复制标题
紫杉醇联合放射治疗治疗皮肤血管肉瘤的疗效：单机构21例回顾性研究
DOI：
10.1111/1346-8138.16273
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Ujiie Hideyuki
中科院分区：
文献类型：
--
作者：
Seo Takashi;Kitamura Shinya;Yanagi Teruki;Ujiie Hideyuki
皮肤血管肉瘤（CAS）是一种罕见的恶性肿瘤，预后较差，其分子病理机制的基础研究和临床前瞻性研究均未取得进展。回顾性研究了28例CAS病例，报告了紫杉烷类放化疗优于常规手术。从那时起，紫杉醇放化疗（PTX + RT）已成为一种标准治疗方法。本文对北海道大学附属医院皮肤科收治的21例CAS患者进行回顾性分析。与其他患者（中位OS 10个月，中位PFS 5个月）相比，最初接受PTX + RT治疗的患者在总生存期（OS）和无进展生存期（PFS）（中位OS 28个月，中位PFS 12个月）方面的预后更好（OS和PFS:p< 0.05， log-rank检验）。我们的结果与之前的一项研究一致，该研究表明PTX + RT后维持紫杉烷化疗比其他干预措施（包括手术）更好。
Cutaneous angiosarcoma (CAS) is a rare malignant tumor with a poor prognosis for which neither basic research on molecular pathomechanisms nor clinical prospective studies have progressed. A retrospective study of 28 CAS cases reported that chemoradiotherapy with taxanes was superior to conventional surgery. Since that time, chemoradiotherapy with paclitaxel (PTX + RT) has become a standard treatment. In this paper, we retrospectively investigate 21 cases of CAS that had been treated in the Department of Dermatology at Hokkaido University Hospital. Patients initially treated with PTX + RT followed by maintenance taxane chemotherapy showed better prognosis in overall survival (OS) and progression‐free survival (PFS) (median OS, 28 months; median PFS, 12 months) compared to others (median OS, 10 months; median PFS, 5 months) (OS and PFS:p< 0.05, log–rank test). Our results are consistent with those of a previous study that suggested that PTX + RT followed by maintenance taxane chemotherapy is a better therapeutic option than other interventions, including surgery.